Get the Stockscreener App
2.27
0.89%
0.02
After Hours:
2.26
-0.01
-0.44%
Eledon Pharmaceuticals Inc stock is traded at $2.27, with a volume of 580.15K.
It is up +0.89% in the last 24 hours and down -16.24% over the past month.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
See More
Previous Close:
$2.25
Open:
$2.25
24h Volume:
580.15K
Relative Volume:
0.73
Market Cap:
$184.46M
Revenue:
Net Income/Loss:
$-78.15M
P/E Ratio:
-2.6478
EPS:
-0.8573
Net Cash Flow:
$-68.89M
1W Performance:
-6.20%
1M Performance:
-16.24%
6M Performance:
-31.21%
1Y Performance:
-17.15%
1-Day Range:
$2.2101
$2.349
1-Week Range:
$2.2101
$2.58
52-Week Range:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.27 | 184.46M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
A kidney transplant study will spotlight what patients report on Oct. 23 - Stock Titan
Eledon Pharmaceuticals (Nasdaq:ELDN)Stock Analysis - Simply Wall Street
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - markets.businessinsider.com
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - GlobeNewswire Inc.
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - FinancialContent
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - The Manila Times
A treatment to prevent kidney transplant rejection will be presented Sept. 22 - Stock Titan
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Australia
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - investing.com
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Canada
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com UK
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - manilatimes.net
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - The Manila Times
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceVolatility Smile - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureETF Flow - dars.gov.et
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Fast Moving Stocks - dars.gov.et
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com India
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com UK
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesLong-Term Guidance - vinanet.vn
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsFloat Adjusted Cap - dars.gov.et
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock DeclinesRevenue Guidance Update - vinanet.vn
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eledon Pharmaceuticals Inc Stock (ELDN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):